異檸檬酸脫氫酶1(IDH1)多克隆抗體(異硫氰酸熒光素標記)
FITC-Linked Polyclonal Antibody to Isocitrate Dehydrogenase 1, Soluble (IDH1)
PICD; IDP; Oxalosuccinate decarboxylase; NADP(+)-specific ICDH; Cytosolic NADP-isocitrate dehydrogenase
- 編號LAH839Mu81
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源抗體標記
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物熒光素
- 原抗體 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應用WB; IHC; ICC; IF.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 907 ¥ 2117 ¥ 3024 ¥ 7560 ¥ 30240
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
該抗體是針對IDH1的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別IDH1。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學：5-20μg/mL;1:25-100
免疫細胞化學：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPH839Mu01 | 異檸檬酸脫氫酶1(IDH1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAH839Mu01 | 異檸檬酸脫氫酶1(IDH1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAH839Mu81 | 異檸檬酸脫氫酶1(IDH1)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| LAH839Mu71 | 異檸檬酸脫氫酶1(IDH1)多克隆抗體(生物素標記) | WB; IHC; ICC. |
參考文獻
| 雜志 | 參考文獻 |
| Molecular & Cellular Proteomics | Identification of IDH1 as a Potential Diagnostic and Prognostic Biomarker for Non-small-cell Lung Cancer by Proteomic Analysis [Mcponline: 008821] |
| Molecular & Cellular Proteomics | Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis [Pubmed: 22064513] |
| Clinical Cancer Research | Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer [Pubmed: 24046070] |
| Onco Targets Ther | The effects of PGC-1α on the proliferation and energy metabolism of malignant endometrial cancer cells [PubMed: 25914546] |
| Oncogene | Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism [Pubmed:29921847] |
| Molecular Oncology | IDH 2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer [Pubmed:29465809] |
| Cancers | Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver … [Pubmed: 32443439] |
| International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer [Pubmed:35689436] |
留言咨詢
